GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166932 | Oral cavity | NEOLP | cellular response to nutrient levels | 42/2005 | 215/18723 | 8.37e-05 | 1.05e-03 | 42 |
GO:002195411 | Oral cavity | NEOLP | central nervous system neuron development | 21/2005 | 81/18723 | 9.05e-05 | 1.12e-03 | 21 |
GO:003600321 | Oral cavity | NEOLP | positive regulation of transcription from RNA polymerase II promoter in response to stress | 10/2005 | 24/18723 | 9.23e-05 | 1.14e-03 | 10 |
GO:003806131 | Oral cavity | NEOLP | NIK/NF-kappaB signaling | 31/2005 | 143/18723 | 9.70e-05 | 1.18e-03 | 31 |
GO:004544622 | Oral cavity | NEOLP | endothelial cell differentiation | 27/2005 | 118/18723 | 1.03e-04 | 1.24e-03 | 27 |
GO:003424922 | Oral cavity | NEOLP | negative regulation of cellular amide metabolic process | 50/2005 | 273/18723 | 1.05e-04 | 1.27e-03 | 50 |
GO:00485686 | Oral cavity | NEOLP | embryonic organ development | 71/2005 | 427/18723 | 1.12e-04 | 1.34e-03 | 71 |
GO:005140332 | Oral cavity | NEOLP | stress-activated MAPK cascade | 45/2005 | 239/18723 | 1.18e-04 | 1.41e-03 | 45 |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:004427031 | Oral cavity | NEOLP | cellular nitrogen compound catabolic process | 74/2005 | 451/18723 | 1.24e-04 | 1.47e-03 | 74 |
GO:000756931 | Oral cavity | NEOLP | cell aging | 29/2005 | 132/18723 | 1.25e-04 | 1.48e-03 | 29 |
GO:003166732 | Oral cavity | NEOLP | response to nutrient levels | 77/2005 | 474/18723 | 1.27e-04 | 1.49e-03 | 77 |
GO:003109832 | Oral cavity | NEOLP | stress-activated protein kinase signaling cascade | 46/2005 | 247/18723 | 1.30e-04 | 1.52e-03 | 46 |
GO:005114615 | Oral cavity | NEOLP | striated muscle cell differentiation | 51/2005 | 283/18723 | 1.37e-04 | 1.60e-03 | 51 |
GO:005076721 | Oral cavity | NEOLP | regulation of neurogenesis | 62/2005 | 364/18723 | 1.50e-04 | 1.71e-03 | 62 |
GO:003462032 | Oral cavity | NEOLP | cellular response to unfolded protein | 23/2005 | 96/18723 | 1.58e-04 | 1.77e-03 | 23 |
GO:006115723 | Oral cavity | NEOLP | mRNA destabilization | 21/2005 | 84/18723 | 1.58e-04 | 1.77e-03 | 21 |
GO:005109031 | Oral cavity | NEOLP | regulation of DNA-binding transcription factor activity | 72/2005 | 440/18723 | 1.66e-04 | 1.84e-03 | 72 |
GO:00326082 | Oral cavity | NEOLP | interferon-beta production | 16/2005 | 56/18723 | 1.80e-04 | 1.97e-03 | 16 |
GO:00326482 | Oral cavity | NEOLP | regulation of interferon-beta production | 16/2005 | 56/18723 | 1.80e-04 | 1.97e-03 | 16 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513014 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513015 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2 | SNV | Missense_Mutation | novel | c.1390N>T | p.Ala464Ser | p.A464S | P00734 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | rs121918482 | c.1292N>A | p.Arg431His | p.R431H | P00734 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | | c.448N>T | p.Ala150Ser | p.A150S | P00734 | protein_coding | tolerated(0.47) | benign(0.06) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2 | insertion | In_Frame_Ins | novel | c.1074_1075insACCCAGCATGAGCTTTCCTGGGATTACTCATAT | p.Ser358_Tyr359insThrGlnHisGluLeuSerTrpAspTyrSerTyr | p.S358_Y359insTQHELSWDYSY | P00734 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
F2 | deletion | Frame_Shift_Del | | c.1015_1025delNNNNNNNNNNN | p.Pro340GlufsTer55 | p.P340Efs*55 | P00734 | protein_coding | | | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
F2 | deletion | Frame_Shift_Del | novel | c.204delN | p.Glu69ArgfsTer52 | p.E69Rfs*52 | P00734 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
F2 | SNV | Missense_Mutation | rs144785536 | c.103C>T | p.Arg35Trp | p.R35W | P00734 | protein_coding | tolerated(0.11) | benign(0.093) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.1755N>T | p.Met585Ile | p.M585I | P00734 | protein_coding | tolerated(0.47) | benign(0.011) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.225N>C | p.Glu75Asp | p.E75D | P00734 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
F2 | SNV | Missense_Mutation | rs775306348 | c.5C>T | p.Ala2Val | p.A2V | P00734 | protein_coding | tolerated_low_confidence(0.14) | benign(0.01) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Anisindione | ANISINDIONE | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | LEPIRUDIN | LEPIRUDIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | ATryn antithrombin | | 24391399 |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | (-)-EPICATECHIN | (-)-EPICATECHIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | hormonal contraceptives for systemic use | | 15208046,28750087,12069454,16769590 |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Odiparcil | ODIPARCIL | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | QUERCETIN | QUERCETIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | AZD-0837 | ATECEGATRAN METOXIL | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Hirudin | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178102998 | DABIGATRAN | |